Research & Development
Veracyte licenses gene signature for idiopathic pulmonary fibrosis
Developed by Yale's Dr. Naftali Kaminski and colleagues, the test predicts rapid disease progression associated with IPF. Experience with the gene signature in a multicenter study was published by Kaminski et al in Lancet Respiratory Medicine (November 2017, Vol. 11, pp. 857-868). Some 200,000 patients in the U.S. and Europe are evaluated for IPF and other interstitial lung diseases every year and knowing the severity of the disease could help guide them to the right treatments, the company noted.
April 23, 2020
Veracyte licenses NanoString diagnostic platform in $50M deal
Per the deal, NanoString is due another $10 million as Veracyte's tests are launched on the platform commercially. NanoString's platform enables the simultaneous analysis of RNA, DNA, or protein targets for up to 800 genes.
December 3, 2019
Veracyte nasal swab test holds its own in lung cancer detection
The South San Francisco, CA-based company is developing the nasal product as a laboratory-developed test for its own CLIA-certified facility and plans to introduce it commercially in early 2021, following additional analytical work and studies, according to Giulia Kennedy, PhD, chief scientific and medical officer. Development is ongoing as part of a broader partnership with Johnson & Johnson related to the early detection of lung cancer.
October 21, 2019
Page 1 of 1